Hookipa Pharma (NASDAQ:HOOK) Coverage Initiated at Morgan Stanley

Share on StockTwits

Investment analysts at Morgan Stanley began coverage on shares of Hookipa Pharma (NASDAQ:HOOK) in a research report issued on Thursday, The Fly reports. The firm set an “overweight” rating on the stock.

A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research raised shares of Hookipa Pharma from a “sell” rating to a “hold” rating in a report on Monday, March 22nd. SVB Leerink reissued a “buy” rating and issued a $28.00 target price on shares of Hookipa Pharma in a research report on Sunday, March 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Hookipa Pharma has an average rating of “Buy” and a consensus price target of $20.14.

NASDAQ HOOK opened at $13.19 on Thursday. The business’s fifty day moving average is $12.73 and its 200-day moving average is $11.38. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.65 and a quick ratio of 5.65. The stock has a market capitalization of $342.54 million, a price-to-earnings ratio of -8.04 and a beta of 1.18. Hookipa Pharma has a one year low of $7.07 and a one year high of $15.52.

Hookipa Pharma (NASDAQ:HOOK) last posted its quarterly earnings results on Wednesday, March 17th. The company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.10. The company had revenue of $5.16 million during the quarter, compared to analyst estimates of $5.11 million. Hookipa Pharma had a negative net margin of 232.00% and a negative return on equity of 39.58%. Research analysts expect that Hookipa Pharma will post -1.84 EPS for the current fiscal year.

In other Hookipa Pharma news, major shareholder Sofinnova Capital Vi Fcpr sold 40,534 shares of the business’s stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $14.54, for a total transaction of $589,364.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 368,283 shares of company stock valued at $5,226,571 over the last quarter. 4.02% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in Hookipa Pharma by 259.1% during the 4th quarter. JPMorgan Chase & Co. now owns 33,931 shares of the company’s stock valued at $376,000 after buying an additional 24,481 shares in the last quarter. Samsara BioCapital LLC grew its stake in Hookipa Pharma by 11.2% during the fourth quarter. Samsara BioCapital LLC now owns 129,660 shares of the company’s stock valued at $1,438,000 after acquiring an additional 13,058 shares in the last quarter. Tudor Investment Corp Et Al bought a new stake in Hookipa Pharma during the 4th quarter worth approximately $222,000. Engineers Gate Manager LP bought a new stake in Hookipa Pharma during the 4th quarter worth approximately $313,000. Finally, Caas Capital Management LP purchased a new stake in Hookipa Pharma in the 4th quarter worth approximately $125,000. Institutional investors and hedge funds own 33.39% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

See Also: How is inflation measured?

The Fly

Analyst Recommendations for Hookipa Pharma (NASDAQ:HOOK)

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.